Market Overview

UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong Antibiotic Portfolio

Related CBST
UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Is This Superbug Drug Company Right for Your Portfolio? (Fox Business)

In a report published Thursday, Oppenheimer analyst Akiva Felt initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with an Outperform rating and $81.00 price target.

In the report, Oppenheimer noted, “Cubist develops acute care drugs for the hospital setting, with an emphasis on antibiotics. We recommend exposure to antibiotics due to the ongoing emergence of multiple-drug-resistant (MDR) infections, which maintain significant unmet medical needs and prevent the landscape from falling entirely to generic drugs. Cubist's broad antibiotic portfolio addresses key unmet needs, and its R&D platform should help maintain a thriving pipeline. Our bullish stance stems from CXA-201 in Phase 3 studies to treat gram-negative infections, with data expected in 4Q13. If it is approved, we expect peak CXA-201 sales to eclipse Cubicin. Moreover, we think CBST shares will benefit from increased M&A activity in biotech, as CXA-201 approval should lead to increased takeout speculation.”

Cubist Pharmaceuticals closed on Wednesday at $63.65.

Latest Ratings for CBST

DateFirmActionFromTo
Nov 2014Credit SuisseDowngradesOutperformNeutral
Nov 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Nov 2014WedbushInitiates Coverage onNeutral

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Akiva Felt OppenheimerAnalyst Color Initiation Analyst Ratings

 

Related Articles (CBST)

Around the Web, We're Loving...

Get Benzinga's Newsletters